NCT04176939View on ClinicalTrials.gov

A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response

PHASE3CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 9, 2019

Primary Completion Date

August 12, 2022

Study Completion Date

June 27, 2024

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

HZ/su vaccine (GSK1437173A)

2 intramuscular (IM) revaccination doses of the HZ/su vaccine administered - first dose at Month 24 and second dose at Month 25.

Trial Locations (15)

333

GSK Investigational Site, Tau-Yuan

1001

GSK Investigational Site, Panama City

1090

GSK Investigational Site, Brussels

28034

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

39008

GSK Investigational Site, Santander

41013

GSK Investigational Site, Seville

M5B 1W8

GSK Investigational Site, Toronto

M5G 2N2

GSK Investigational Site, Toronto

00029

GSK Investigational Site, Helsinki

06351

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

08035

GSK Investigational Site, Barcelona

08036

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04176939 - A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response | Biotech Hunter | Biotech Hunter